Page 46 - Amgen News Today

The Food and Drug Administration on Thursday approved an innovative new treatment for patients with a form of lung cancer. It is to be used only by patients…

NEW YORK (AP) — The Dow Jones Industrial Average just topped 40,000 for the first time, the latest pop in what’s been a surprisingly good year for Wall Street. But just like New Year’s represents an arbitrary point in time in the Earth’s revolution around the sun, such milestones for the Dow don’t mean that […]

By Ben Glickman Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer. The pharmaceutical company said that Imdelltra, an...

The group is led by Sige Gutman, who has over 20 years of industry experience

Plus takeaways from Berkshire’s annual meeting and new research on Apple and Amazon.

Apollon Wealth Management LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 51.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 20,516 shares of the medical research company’s stock after purchasing an additional 6,991 shares during the period. Apollon Wealth Management LLC’s holdings in […]

Apollon Wealth Management LLC grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 51.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,516 shares of the medical research company’s stock after purchasing an additional 6,991 shares during the quarter. […]

Amgen (NASDAQ:AMGN – Free Report) had its target price hoisted by Morgan Stanley from $271.00 to $310.00 in a research note issued to investors on Friday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the medical research company’s stock. Other research analysts also recently issued research reports about the stock. SVB Leerink […]

ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30...

Clifford Swan Investment Counsel LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 40,108 shares of the medical research company’s stock after selling 307 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Amgen were worth $11,552,000 at the end […]